-
Looking forward to pharmaceutical research innovation, hoping that drugs will cure the "new crown
Time of Update: 2023-01-01
Promote drug research and development, more cutting-edge technologies are put into use, and intelligent simplification of complex data screening,Looking forward to "tomorrow", no matter how severe the epidemic is, it will also be defeated by the hands of mediciners, so that society will no longer talk about the "crown" color change, and let people live freely and happily.
-
Domestic new drugs "Jinbao" accelerated, and 14 varieties such as Hengrui and Rongchang became the focus
Time of Update: 2022-11-26
In 2022, 25 rare disease drugs and children's drugs were shortlisted A few days ago, the National Health Insurance Administration officially announced that the expert review process in the adjustment of the national medical insurance catalogue in 2022 has ended, and it will soon enter the negotiation and bidding process.
-
Double happiness for Hengrui
Time of Update: 2022-05-21
Table 1: The ANDA number that Hengrui has obtained Source: Minet Global Listed Drug Database On April 15, Jiangsu Hengrui Pharmaceutical announced that the company's abbreviated new drug application (ANDA) for gadoteric acid meglumine injection submitted to the US FDA was approved, which means that the product can be produced and sold in the US market .
-
Leuprolide injection emulsion, a subsidiary of Changchun Hi-Tech Holdings, was approved for clinical use
Time of Update: 2022-04-26
Changchun Hi-Tech announced that its holding subsidiary Jinsai Pharmaceuticals Leuprolide Injection Emulsion has recently received a drug clinical trial approval notice from NMPA . According to the
-
The 5 billion antihypertensive drug market has ushered in strong competitors
Time of Update: 2022-02-18
Recently, Guangzhou Poinsettia Pharmaceuticals issued an announcement stating that its valsartan oral solution, which was reported to be produced as a generic class 3 product, has entered the stage of administrative approval .
-
Scientists reveal how triclosan damages the gut
Time of Update: 2022-01-21
However, a growing body of research is linking triclosan to gut microbiota and intestinal inflammation .
However, a growing body of research is linking triclosan to gut microbiota and intestinal inflammation .
However, a growing body of research is linking triclosan to gut microbiota and intestinal inflammation .
-
Shaanxi Provincial Food and Drug Administration Solicits Opinions on Implementation Rules for Credit Restoration of Drug Supervision and Administration
Time of Update: 2021-10-22
Article 7 [Application Conditions] If a party has been included in the drug safety "blacklist" for one year and meets the following circumstances, he can apply for credit restoration in accordance with the provisions of these Measures: (1) Has consciously performed the obligations specified in the administrative penalty decision; (2) Has taken the initiative to eliminate the harmful consequences and adverse effects; (3) Has not received severe administrative penalties from the drug regulatory authority .
-
Express first-line treatment of advanced liver cancer, ALK-1 monoclonal antibody/Opdivo combination is clinically approved in China
Time of Update: 2021-10-21
, announced that China National Medical Products Administration (NMPA) has recently approved its ALK-1 monoclonal antibody (GT90001C), and Bristol-Myers Squibb (BMS) anti-PD-1 monoclonal antibody A clinical trial of nivolumab (English trade name Opdivo) in combination for the treatment of patients with advanced hepatocellular carcinoma (HCC) without systemic treatment .
com/news-releases/kintor-pharma-announces-china-nmpa-approves-clinical-trial-of-alk-1-and-nivolumab-combination-therapy-for-the-first-line-treatment-of-advanced -hepatocellular-carcinoma-301396741.
-
Professor Zhong Diansheng and Professor Meng Fanlu: "Talking" about the immunotherapy of advanced solid tumors, "drawing" a new way for long-term survival
Time of Update: 2021-06-11
Clinical studies have confirmed that MSI-H/ Mismatch repair deficiency (dMMR) can effectively predict whether patients with advanced solid tumors will benefit from immune checkpoint inhibitor therapy, and has nothing to do with specific cancer types [2].
-
Kelun Pharmaceutical obtained the drug registration certificate for sunitinib malate capsules
Time of Update: 2021-05-03
It is understood that sunitinib malate capsules developed by Pfizer, approved in the United States in 2006, after another in Japan, Europe approved the listing Union and other countries and regions, in 2007 the country approved import for inoperable fine advanced renal cell carcinoma, imatinib mesylate stromal tumors and metastatic unresectable between high failure or intolerant gastrointestinal differentiation of pancreatic neuroendocrine tumor progression.
-
Redsiwe is authorized for emergency use by fda in the United States
Time of Update: 2021-03-03
The EUA is based on available data from two global clinical trials - the placebo-controlled Phase III trial conducted by the National Institute of Allergy and Infectious Diseases (NIAID) for patients with moderate to severe new coronavirus pneumonia, including critically ill patients, and the global Phase III trial of Rydersiwe's 5-day and 10-day dosage time in Gilead's assessment of critically ill patients.
-
More life-saving emergency medicine or included in health insurance
Time of Update: 2021-02-22
days ago, CCTV broadcast the topic, announced the latest progress of medical insurance said: the national medical insurance drug catalog adjustment work is under intense, the future will have more life-saving drugs into the medical insurance reimbursement directory, to ensure that people can afford to see the disease.
-
The synthetic biopharmaceonceline (Carrimycin) is used to treat COVID-19: The FDA has allowed phase III clinical trials
Time of Update: 2021-01-13
Carrimycin has become the world's first synthetic biologic drug for patients with severe COVID-19, and the U.S. Food and Drug Administration (FDA) has allowed Phase III clinical trials of Carrimycin's treatment of COVID-19.
-
Heavy! Health care catalog adjustment enters a critical moment! Six provinces and two districts collection program called out
Time of Update: 2020-11-08
According to the schedule of adjustment of the entire health insurance catalogue, according to the 2020 National Health Insurance Drug Catalog Adjustment Work Programme, the 2020 catalogue adjustment is divided into five stages: preparation, enterprise declaration, expert review, negotiation and bidding, and publication of the results, if progress is smooth, it is expected that all work will be completed by the end of this year.
-
The health insurance bureau raided the pharmacy and was fined
Time of Update: 2020-10-25
Two months after the death of the insured person, some people said that their relatives, with their health insurance card to the pharmacy to buy medicine, the result of the health insurance bureau ra
